...
首页> 外文期刊>Kidney Research and Clinical Practice >Mineral and Bone Disorder in Children with Chronic Kidney Disease Stage I to V (Predialysis)
【24h】

Mineral and Bone Disorder in Children with Chronic Kidney Disease Stage I to V (Predialysis)

机译:慢性肾脏疾病I至V期(透析前)患儿的矿物质和骨骼疾病

获取原文
           

摘要

Purposes: To evaluate the mineral and bone disorders in children with chronic kidney disease (CKD) stage I to V predialysis. Methods: Pediatric subcohort of KNOW-CKD (KoreaN cohort study for Outcome in patients With CKD) enrolled children (younger than 20 years) with CKD stage I-V (pre-dialysis) from five major pediatric nephrology centers in Korea and collected medical data associated with CKD-mineral and bone disorder. Results: Total number of 300 patients (male:female=199:101) was included in this study. Serum phosphorus (mean +/- standard deviation 4.89+/-0.75, 4.6+/-0.83, 4.63+/-0.85, 5.13+/-1.37, 5.35+/-1.2 from CKD stage I to V, p=0.0002), fibroblast growth factor (FGF)-23 (32.29+/-42.04, 41.33+/-41.00, 70.68+/-121.06, 67.9+/-66.95, 121.74+/-139.36, p=0.0030) and the prevalence of hyperphosphatemia (8.51%, 10.64%, 25.53%, 25.53%, 29.79%, p=0.010) increased as CKD progressed. Intact parathyroid hormone (iPTH) increased (40.84+/-40.37, 44.13+/-20.2, 78.93+/-65.21, 181.39+/-183.86, 313.85+/-324.95, p<0.001) and serum 1,25D3 level decreased (47.52+/-21.32, 37.43+/-12.26, 36.86+/-25.97, 28.29+/-15.81, 34.11+/-21.34, p<0.001) significantly as CKD aggravated. Serum iPTH (r=-0.608, p<0.0001) and FGF-23 (r=-0.4943, p<0.0001) showed negative correlation whereas 1,25D3 (r=0.3288, <0.0001) showed positive correlation with glomerular filtration rate. FGF-23 showed positive correlation with serum phosphorus (r=0.3342, p<0.0001), iPTH (r=0.3214, p<0.0001) and proteinuria (r=0.3609, p<0.0001), and negative correlation with urine phosphorus (r=-0.2597, p=0.0006). The prevalence of patients with increased alkaline phosphatase level increased significantly as CKD progressed (5.66%, 15.09%, 39.62%, 16.98%, 22.64%, p=0.042), which was due to increased prevalence of hyperparathyroidism (p<0.001). Active form vitamin D (0%, 3.77%, 11.88%, 40.74%, 68.89%, p<0.0001), calcium (2.13%, 0%, 9.90%, 4.44%, 62.22%, p<0.0001) and non-calcium phosphorous binders (0%, 0%, 0%, 0%, 13.33%, p<0.0001) were prescribed significantly more often in advanced CKD. Calcium x phosphorus was significantly increased in advanced CKD (11.59%, 17.39%, 28.26%, 21.01%, 21.74%, p=0.002). Conclusion: As CKD progressed, hyperphosphatemia, hyperparathyroidism and 1,25D3 deficiency increased, serum FGF-23 level increased and urinary phosphorus excretion decreased in children with CKD stage I to V predialysis.
机译:目的:评估慢性肾病(CKD)I至V期透析前儿童的矿物质和骨骼疾病。方法:从韩国的五个主要儿科肾脏病学中心招募了年龄在20岁以内的CKD IV期(透析前)的儿童(KCK病人的韩国队列研究)的小儿亚组。 CKD-矿物质和骨骼疾病。结果:本研究共纳入300例患者(男性:女性= 199:101)。血清磷(从CKD阶段I到V的平均+/-标准偏差4.89 +/- 0.75、4.6 +/- 0.83、4.63 +/- 0.85、5.13 +/- 1.37、5.35 +/- 1.2,p = 0.0002),成纤维细胞生长因子(FGF)-23(32.29 +/- 42.04,41.33 +/- 41.00,70.68 +/- 121.06,67.9 +/- 66.95,121.74 +/- 139.36,p = 0.0030)和高磷血症的患病率(8.51随着CKD的进展,%,10.64%,25.53%,25.53%,29.79%,p = 0.010)增加。完整的甲状旁腺激素(iPTH)增加(40.84 +/- 40.37,44.13 +/- 20.2,78.93 +/- 65.21,181.39 +/- 183.86,313.85 +/- 324.95,p <0.001)和血清1,25D3水平降低(随着CKD的加重,显着增加了47.52 +/- 21.32、37.43 +/- 12.26、36.86 +/- 25.97、28.29 +/- 15.81、34.11 +/- 21.34,p <0.001)。血清iPTH(r = -0.608,p <0.0001)和FGF-23(r = -0.4943,p <0.0001)呈负相关,而1,25D3(r = 0.3288,<0.0001)与肾小球滤过率呈正相关。 FGF-23与血清磷(r = 0.3342,p <0.0001),iPTH(r = 0.3214,p <0.0001)和蛋白尿(r = 0.3609,p <0.0001)呈正相关,与尿磷呈负相关(r = -0.2597,p = 0.0006)。随着CKD的进展,碱性磷酸酶水平升高的患者患病率显着增加(5.66%,15.09%,39.62%,16.98%,22.64%,p = 0.042),这是由于甲状旁腺功能亢进症的患病率增加(p <0.001)。活性形式的维生素D(0%,3.77%,11.88%,40.74%,68.89%,p <0.0001),钙(2.13%,0%,9.90%,4.44%,62.22%,p <0.0001)和非钙在晚期CKD中,磷粘结剂(0%,0%,0%,0%,13.33%,p <0.0001)的使用频率明显更高。晚期CKD中钙x磷显着增加(11.59%,17.39%,28.26%,21.01%,21.74%,p = 0.002)。结论:随着CKD的进展,CKD I至V期透析前儿童的血磷过多,甲状旁腺功能亢进和1,25D3缺乏症增加,血清FGF-23水平升高,尿磷排泄减少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号